Lupin Pharmaceuticals Tydemy oral contraceptive recall: Out of Specification Results
Out of Specification Results
The hazard: Potency, impurity or stability failure
The recall concerns the strength or purity of the medicine rather than contamination of it, which changes what you should do about a dose you have already taken.
What the notice says: Regardless, Lupin is recalling these two batches because if there were a significant reduction in the amount of inactive content (ascorbic acid), this could potentially impact the effectiveness of the product which could potentially result in unexpected pregnancy.
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Published
- July 29, 2023
- Risk level
- Elevated risk
- Issued by
- U.S. Food and Drug Administration
- Brand
- Lupin Pharmaceuticals
- Product type
- Prescription & OTC drugs
- Distribution
- Nationwide
- UPC codes
- 368180904731
- Reports of harm
- To date, Lupin has received no reports of adverse events related to either recalled batches.
Products covered by this recall
Tydemy oral contraceptive
What the company announced
Baltimore, Maryland, July 28, 2023: Lupin Pharmaceuticals Inc. (Lupin) is voluntarily recalling two (2) lots of Tydemy (Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets 3mg/0.03mg/0.451 mg and Levomefolate Calcium Tablets 0.451 mg) to the patient (consumer/user) level due to out of specification (OOS) test results at the 12-month stability time point. Specifically, one lot (L200183) tested low for ascorbic acid (an inactive ingredient) and high for a known impurity.
To date, Lupin has received no reports of adverse events related to either recalled batches. Regardless, Lupin is recalling these two batches because if there were a significant reduction in the amount of inactive content (ascorbic acid), this could potentially impact the effectiveness of the product which could potentially result in unexpected pregnancy.
Tydemy is estrogen/progestin oral contraceptive (COC) indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception. Tydemy is packaged in 28’s blister. One such blister was then packed in a pouch along with one printed sleeve, one pack insert (with day label) and one oxygen absorber (Stabilox) sachet. The three pouches were packed in one carton.
The lots were distributed nationwide in the US to wholesalers, drug chains, mail order pharmacies and supermarkets. The recalled lots are included in the table below:
- Product: TydemyTM · Lot No: L200183 · Expiry: Jan. 2024 · NDC(s): 68180-904-71 (1 Blister of 28 tablets each) 68180-904-73 (3 Blister of 28 tablets each) · UPC: 368180904731 · Distribution Dates: June 2022 to May 2023
- Product: L201560 · Lot No: Sep. 2024
Lupin is notifying its wholesalers, distributors, drug chains, mail order pharmacies and supermarkets by phone and through recall notification and is arranging for the return of all the recalled product lots.
Patients taking Tydemy are advised to continue taking their medication and immediately contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.
Wholesalers, distributors and retailers that have Tydemy that is being recalled should discontinue distribution of the recalled product lots immediately.
Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (866) 480-8206 Monday – Friday 09:00 am to 05:00 pm EST. For reimbursement, please have the recalled lots returned to Inmar Rx Solutions, Inc.; the lot number can be found on the side of the carton. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Complete and submit the report Online
Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
About Lupin Pharmaceuticals
Lupin Pharmaceuticals, Inc. is the U.S. based wholly-owned subsidiary of Lupin Limited and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions. Together, all Lupin-owned entities combine to make up the 8th largest generic pharmaceutical company in the world by revenue size. Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality medications across many treatment areas. Lupin Pharmaceuticals Inc.’s branded pharmaceuticals division, is the provider of products designed to help prevent and manage women’s health conditions with serious health consequences.
© 2023 Lupin Pharmaceuticals, Inc. All rights reserved.
Reproduced from the company announcement posted on fda.gov. Links and contact forms in the original are not repeated here; the official notice below has them.
Check your product
The notice names 7 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
UPC / barcode
Read the twelve digits under the barcode on the package.
- 368180904731
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- L200183
- Sep. 2024
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- Jan. 2024
Model or item number
On the rating label, the box or the instruction sheet.
- L201560
Package size
Match the net weight or the piece count on the front of the pack.
- 3 mg
- 0.03 mg
Codes are lifted verbatim from the FDA — Company recall announcements notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Lupin Pharmaceuticals — The recall concerns the strength or purity of the medicine rather than contamination of it, which changes what you should do about a dose you have already taken.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Report any change in how the medicine is working to FDA MedWatch, which is where most of these signals originate.
- Do not stop a prescription on your own. For most conditions an uncertain dose is safer than no dose while you get advice.
- Call your prescriber or pharmacist and ask whether to swap the lot, re-test, or change nothing.
Getting a replacement supply
Do not let a refund question interrupt your treatment. Deal with the supply first and the money second.
- Call the pharmacy before you run low. They can see which lot they dispensed to you and will usually swap it the same day.
- Insurers do not normally count a recall replacement against a refill limit. If one is refused, ask the pharmacist to call it through as a recall override.
- Over-the-counter products are refunded at the till like any other purchase; the recall notice on your phone is enough to explain the return.
- If the manufacturer runs a direct reimbursement form, it will be linked from the official notice on this page.
Company contact: Lupin Pharmaceuticals, Inc. — Consumers: Inmar Rx Solutions, Inc, (866) 480-8206 — Media: Shweta Munjal, [email protected]
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Company recall announcements record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Lupin Pharmaceuticals prescription & otc drugs recalled?
Out of Specification Results Regardless, Lupin is recalling these two batches because if there were a significant reduction in the amount of inactive content (ascorbic acid), this could potentially impact the effectiveness of the product which could potentially result in unexpected pregnancy.
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: UPC 368180904731; lot code L200183, Sep. 2024; best-by date Jan. 2024; model number L201560. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
Call the pharmacy before you run low. They can see which lot they dispensed to you and will usually swap it the same day.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class II · 2 months ago
Lupin Pharmaceuticals Inc. Clobetasol Propionate Cream USP, 0.05%, 60 g tube recall: Failed content uniformity specifications
Failed content uniformity specifications.
-
Class II · 4 months ago
Lupin Pharmaceuticals Inc. Glucagon Emergency Kit for Low Blood Sugar recall: CGMP deviation: OOS result observed for the Gliding Force functionality test
CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.
-
Class II · 4 months ago
Lupin Pharmaceuticals Inc. prednisoLONE Acetate Ophthalmic Suspension, USP, 1% recall: Presence of Foreign Substance
Presence of Foreign Substance
-
Class II · 5 months ago
Lupin Pharmaceuticals Inc. Liraglutide Injection, 18 mg/3 mL recall: Presence of particulate matter: a white thread-like structure in the cartridge
Presence of particulate matter: a white thread-like structure in the cartridge
-
Class II · 11 months ago
Lupin Pharmaceuticals Inc. Ganirelix Acetate Injection, 250 mcg/0.5mL recall: Failed impurities/degradation specifications: out of specification results
Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
-
Class II · 11 months ago
Lupin Pharmaceuticals Inc. Sertraline Hydrochloride Tablets USP, 100 mg recall: Defective container - seal not adhering to bottles
Defective container - seal not adhering to bottles